Other equities research analysts have also recently issued reports about the stock. Analysts at Auriga reiterated a “buy” rating on shares of Affymax in a research note to investors on Tuesday, May 8th. Separately, analysts at WBB Securities downgraded shares of Affymax from a “strong-buy” rating to a “buy” rating in a research note to investors on Tuesday, May 8th. They now have a $17.00 price target on the stock, up previously from $9.00. Finally, analysts at Piper Jaffray (NYSE: PJC) reiterated an “overweight” rating on shares of Affymax in a research note to investors on Friday, April 13rd.
Affymax opened at 14.10 on Monday. Affymax has a 1-year low of $3.93 and a 1-year high of $16.25. The company’s market cap is $509.1 million.
Affymax, Inc. is a biopharmaceutical company developing drugs to improve the treatment of serious and often life-threatening conditions.